A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Descripteurs (mots clés)
Thésaurus Mesh
> T > Tumeurs prostatiques résistantes à la castration > Tumeurs prostatiques résistantes à la castration / traitement médicamenteux
Tumeurs prostatiques résistantes à la castration / traitement médicamenteux
Ajouter le résultat dans votre panier Affiner la recherche
Etendre la recherche sur niveau(x) vers le bas
First-line management of metastatic castrate-resistant prostate cancer patients : audit of real-life practices / Anthony Turpin in Bulletin du cancer, vol. 104, 6 (Juin 2017)
[article]
in Bulletin du cancer > vol. 104, 6 (Juin 2017) . - p. 552-558
Titre : First-line management of metastatic castrate-resistant prostate cancer patients : audit of real-life practices Titre original : État des lieux de la prise en charge des patients atteints de cancer de la prostate résistant à la castration en première ligne par les oncologues français Type de document : article de périodique Auteurs : Anthony Turpin ; David Pasquier ; Christophe Massard ; [et al.] Année de publication : 2017 Article en page(s) : p. 552-558 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus HELB]:Paramédical:Docétaxel
[Thésaurus HELB]:Paramédical:Enzalutamide
[Thésaurus Mesh]:T:Tumeurs prostatiques résistantes à la castration:Tumeurs prostatiques résistantes à la castration / traitement médicamenteux
[Thésaurus Mesh]Antinéoplasiques
[Thésaurus Mesh]Antinéoplasiques hormonaux
[Thésaurus Mesh]Tumeurs prostatiques résistantes à la castrationMots-clés : Tumeurs prostatiques résistantes à la castration / traitement médicamenteux Docétaxel Antinéoplasiques hormonaux Enzalutamide Résumé : Background
No reliable guidelines are available for choosing the best option between docetaxel and new hormonal therapies (NHTs) (i.e., abiraterone and enzalutamide) in first-line therapy for metastatic castration-resistant prostate cancer (mCRPC) patients. We performed an audit of real-life practices.
Methods
We built an online questionnaire and distributed it with the help of French oncology networks. This questionnaire was sent to 481 physicians who treat patients with mCRPC. All of the answers were declarative, individual, and anonymized. A descriptive analysis was done. A univariate logistic regression analysis was performed for the criteria of choice between docetaxel and NHTs.
Results
From March to July 2015, 109/481 physicians (22.6%) completed the questionnaire. The selection criteria for initially choosing docetaxel were as follows: presence of visceral metastases (79.8%), heavy tumor burden (68.8%), aggressive tumor disease (66.1%), and short-term efficacy of castration (66.1%). The selection criteria for initially choosing NHTs were as follows: long-term efficacy of castration (66.1%), higher age (67.9%), low tumor grade (56.9%), and absence of symptoms (54.1%). With docetaxel, the first tumor assessment was typically performed after three (1–6) cycles, including prostate-specific antigen (PSA) testing (96.3%), a thoraco-abdominopelvic CT scan (68.8%), and bone scintigraphy (59.6%). With NHTs, tumor assessment was mainly performed after 3 months of treatment (1–6) and included PSA testing, a thoraco-abdominopelvic CT, and bone scintigraphy in 90.8%, 61.5%, and 63.3% of cases, respectively.
Conclusions
This is the first study assessing real-life practices among physicians who treat patients with mCRPC. These practices were found to be homogeneous.Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité B Périodique Erasme - périodiques Périodiques Disponible